NewsSource: EClinCloud Official Website Archive

Ark Biosciences Successfully Completes Phase III Clinical Study of Aizhida™, Supported Throughout by EClinCloud eCOA

4 min readEClinCloud Editorial Team
Ark Biosciences smoothly completes the Aizhida™ Phase III clinical study, supported throughout by EClinCloud eCOA! Archived article cover

On March 24, Shanghai Ark Biopharmaceutical Technology Co., Ltd. ("Ark Biosciences") announced that the Phase III clinical study of its new drug Aizhida™ (AK0901) for the treatment of attention-deficit/hyperactivity disorder (ADHD) in children and adults has been successfully completed. This milestone marks a solid step forward for Ark Biosciences in drug development for pediatric psychiatric disorders and is expected to provide new treatment options and a better treatment experience for pediatric and adult patients with ADHD in China.

As a long-term partner of Ark Biosciences, EClinCloud provided strong support for the Phase III clinical study of Aizhida™ through its digital eCOA solution and one-stop services, ensuring more complete, accurate, timely, and compliant data collection, significantly improving data quality and study efficiency, and providing more reliable clinical evidence for new drug development.

 

EClinCloud sincerely congratulates Ark Biosciences on this important milestone and looks forward to continuing to work together in the future to achieve further success and accelerate the new drug development process.

 

The following content is reposted from the official WeChat account of Ark Biosciences

ADHD is a common chronic neurodevelopmental disorder that begins in childhood, with effects that can persist into adulthood. It is characterized primarily by inattention and/or hyperactivity-impulsivity that is inconsistent with the individual's developmental level. Its global incidence in children is approximately 7.2%, with 60% to 80% persisting into adolescence and 50.9% persisting as adult ADHD. Approximately 65% of affected children have one or more comorbidities. ADHD not only impairs learning functioning, but also involves other multifaceted impairments across the entire lifespan. In China, the prevalence of ADHD among children and adolescents is 6.4%, affecting more than 23 million individuals; however, the types of medications currently available for treating ADHD are limited, the efficacy and safety of existing medications still cannot fully meet clinical needs, and some patients are unable to adhere to treatment due to inadequate efficacy, side effects, or dosing inconvenience.

写有ADHD评估字样的记录板插图  

Azstarys ™ (AK0901) openable capsules are the world's first and currently only combination formulation containing immediate-release dexmethylphenidate (d-MPH) and the prodrug serdexmethylphenidate (SDX). It acts on the reuptake of the brain neurotransmitters dopamine and norepinephrine, increasing their concentrations in the synapse, thereby enhancing neurotransmitter transmission efficiency and improving ADHD symptoms. Azstarys™ is a best-in-class innovative therapeutic drug for patients with attention-deficit/hyperactivity disorder (ADHD). It was approved for marketing in the United States in March 2021 and is the first new-generation methylphenidate drug approved by the FDA in nearly 20 years, offering distinct advantages in safety and therapeutic mechanism.

The Phase III clinical study of Aizhida™ (AK0901) in China was co-led by Beijing Anding Hospital, Capital Medical University and Peking University Sixth Hospital and conducted across 8 clinical trial centers nationwide to evaluate the efficacy, safety, and tolerability of oral Aizhida™ in pediatric trial participants with ADHD aged 6 to 12 years. The study results showed that the primary endpoint and key secondary endpoints were met, with statistically significant improvements achieved at all visit time points compared with placebo. This provides solid, strong evidence-based support for patients with ADHD in China to gain earlier and faster access to the latest global medicines.

 

Professor Zheng Yi, Chief Expert at Beijing Anding Hospital, Capital Medical University, said:

“The Phase III study of Aizhida™ (AK0901) systematically validated its therapeutic value in children with ADHD in China through a rigorous multicenter, randomized controlled design. As a next-generation methylphenidate medication, the synergistic action of its immediate-release and prodrug components not only achieves rapid symptom control, but also reduces adherence challenges caused by the fluctuations of conventional medications through a smooth plasma concentration curve, better aligning with the tiered needs of school-age children for 'classroom focus + after-school behavior management,' which makes disease-course management more scientific. The study data provide high-quality, evidence-based support for establishing a full-course ADHD management model tailored to the characteristics of Chinese children, and we look forward to it advancing treatment upgrades and benefiting more patients and families after its launch.”

 

Professor Liu Jing, Director of the Child Mental Health Center at Peking University Sixth Hospital, said:

"This study provides breakthrough validation of the efficacy and safety of Aizhida™ (AK0901) in Chinese pediatric patients with ADHD. Its proprietary immediate-release/prodrug biphasic-release delivery system significantly reduces the peak-to-trough fluctuations of conventional methylphenidate medications, not only maintaining stable symptom control but also reducing the risk of drug abuse, which holds important clinical value for patients with ADHD who require years of continuous intervention. This achievement not only addresses core clinical concerns regarding the safety of long-term medication use in children, but also provides a new approach to balancing efficacy needs and long-term medication safety in pediatric patients with ADHD. We look forward to Aizhida™ receiving marketing approval and entering clinical use soon, so that more Chinese children with ADHD can grow up healthy."

 

Dr. Wu Zheng, Chairman and Chief Executive Officer of ArkBio, stated:

“Completing the Phase III clinical study of Aizhida™ (AK0901) smoothly and on schedule is a productive, key advance for Ark Biosciences in ADHD drug development. We sincerely thank all trial participants, expert teams, and partners who took part in this study for their efforts and contributions. We will build on this momentum to continue advancing scientific progress in ADHD drug development.”